About Natera (NASDAQ:NTRA)
Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090
Debt
Debt-to-Equity Ratio-7.05%
Current Ratio1.37%
Quick Ratio1.29%
Price-To-Earnings
Trailing P/E Ratio-4.57
Forward P/E Ratio-5.92
P/E GrowthN/A
Sales & Book Value
Annual Sales$210.94 million
Price / Sales2.82
Cash FlowN/A
Price / CashN/A
Book Value($0.19) per share
Price / Book-57.68
Profitability
EPS (Most Recent Fiscal Year)($2.40)
Net Income$-136,310,000.00
Net Margins-64.61%
Return on Equity-357.12%
Return on Assets-71.89%
Miscellaneous
Employees893
Outstanding Shares54,180,000
Natera (NASDAQ:NTRA) Frequently Asked Questions
What is Natera's stock symbol?
Natera trades on the NASDAQ under the ticker symbol "NTRA."
How were Natera's earnings last quarter?
Natera Inc (NASDAQ:NTRA) issued its quarterly earnings data on Tuesday, March, 13th. The medical research company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.27. The medical research company had revenue of $53.80 million for the quarter, compared to analyst estimates of $56.83 million. Natera had a negative return on equity of 357.12% and a negative net margin of 64.61%. View Natera's Earnings History.
What price target have analysts set for NTRA?
5 Wall Street analysts have issued 12-month price targets for Natera's shares. Their forecasts range from $12.00 to $16.00. On average, they expect Natera's stock price to reach $14.75 in the next twelve months. View Analyst Ratings for Natera.
Who are some of Natera's key competitors?
Who are Natera's key executives?
Natera's management team includes the folowing people:
- Dr. Matthew Rabinowitz Ph.D., Co-Founder, Chairman, Chief Exec. Officer and Pres (Age 45)
- Mr. Jonathan Sheena M.Eng., Co-Founder, Chief Technology Officer and Director (Age 45)
- Mr. Michael Brophy M.B.A., Chief Financial Officer (Age 38)
- Mr. Steve Chapman, Chief Operating Officer
- Mr. Daniel Rabinowitz L.L.M., LL.M., Corp. Sec. and Gen. Counsel
When did Natera IPO?
(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
Has Natera been receiving favorable news coverage?
Media stories about NTRA stock have trended somewhat positive on Sunday, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Natera earned a news impact score of 0.17 on Accern's scale. They also assigned news stories about the medical research company an impact score of 46.23 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Natera?
Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Natera's stock price today?
One share of NTRA stock can currently be purchased for approximately $10.96.
How big of a company is Natera?
Natera has a market capitalization of $600.89 million and generates $210.94 million in revenue each year. The medical research company earns $-136,310,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Natera employs 893 workers across the globe.
How can I contact Natera?
Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090.
MarketBeat Community Rating for Natera (NTRA)
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Natera (NASDAQ:NTRA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Natera in the last 12 months. Their average twelve-month price target is $14.75, suggesting that the stock has a possible upside of 34.58%. The high price target for NTRA is $16.00 and the low price target for NTRA is $12.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $14.75 | $14.3333 | $14.3333 | $16.50 |
| Price Target Upside: | 34.58% upside | 45.52% upside | 45.52% upside | 29.31% upside |
Natera (NASDAQ:NTRA) Consensus Price Target History
Natera (NASDAQ:NTRA) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Natera (NASDAQ:NTRA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Natera (NASDAQ NTRA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.18%
Institutional Ownership Percentage: 67.08%
Natera (NASDAQ NTRA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/26/2018 | Michael Burkes Brophy | CFO | Sell | 1,449 | $9.74 | $14,113.26 | 4,468 |  |
| 3/26/2018 | Steven Leonard Chapman | COO | Sell | 1,997 | $9.74 | $19,450.78 | 4,468 | |
| 9/6/2017 | Jonathan Sheena | Insider | Sell | 120,000 | $12.54 | $1,504,800.00 | 533,208 | |
| 4/5/2017 | Herm Rosenman | Director | Sell | 1,809 | $8.55 | $15,466.95 | 42,950 | |
| 1/4/2017 | Herm Rosenman | CFO | Sell | 1,849 | $11.87 | $21,947.63 | 33,409 | |
| 12/22/2016 | Jonathan Sheena | Insider | Sell | 16,213 | $12.00 | $194,556.00 | 645,972 | |
| 12/20/2016 | Jonathan Sheena | Insider | Sell | 1,087 | $12.00 | $13,044.00 | 630,846 | |
| 12/13/2016 | Jonathan Sheena | Insider | Sell | 2,700 | $12.00 | $32,400.00 | 632,459 | |
| 12/6/2016 | Herm Rosenman | CFO | Sell | 1,828 | $11.83 | $21,625.24 | 30,237 | |
| 12/5/2016 | Matthew Rabinowitz | CEO | Sell | 14,021 | $12.02 | $168,532.42 | 1,888,644 | |
| 12/1/2016 | Matthew Rabinowitz | CEO | Sell | 56,072 | $12.01 | $673,424.72 | 1,942,572 | |
| 11/28/2016 | Matthew Rabinowitz | CEO | Sell | 146,756 | $12.50 | $1,834,450.00 | 2,020,876 | |
| 11/21/2016 | Jonathan Sheena | Insider | Sell | 32,505 | $12.00 | $390,060.00 | 630,165 | |
| 11/3/2016 | Herm Rosenman | CFO | Sell | 1,852 | $7.98 | $14,778.96 | | |
| 10/6/2016 | Herm Rosenman | CFO | Sell | 1,773 | $11.53 | $20,442.69 | 22,051 | |
| 10/5/2016 | Jonathan Sheena | Insider | Sell | 1,600 | $12.00 | $19,200.00 | 617,151 | |
| 9/6/2016 | Herm Rosenman | CFO | Sell | 1,822 | $10.21 | $18,602.62 | 18,873 | |
| 8/2/2016 | Herm Rosenman | CFO | Sell | 1,833 | $12.98 | $23,792.34 | 15,706 | |
| 7/6/2016 | Herm Rosenman | CFO | Sell | 1,824 | $12.10 | $22,070.40 | 12,530 | |
| 7/1/2016 | Matthew Rabinowitz | CEO | Sell | 104,892 | $12.14 | $1,273,388.88 | 2,167,354 | |
| 6/19/2016 | Jonathan Sheena | CTO | Sell | 188,442 | $11.94 | $2,249,997.48 | 598,420 | |
| 6/19/2016 | Matthew Rabinowitz | CEO | Sell | 732,831 | $11.94 | $8,750,002.14 | 2,876,595 | |
| 6/19/2016 | Roelof Botha | Director | Buy | 837,521 | $11.94 | $10,000,000.74 | | |
| 6/2/2016 | Herm Rosenman | CFO | Sell | 1,806 | $12.04 | $21,744.24 | 9,336 | |
| 2/1/2016 | Jonathan Sheena | CTO | Sell | 10,000 | $8.03 | $80,300.00 | 615,551 | |
| 1/5/2016 | Matthew Rabinowitz | CEO | Sell | 54,683 | $10.37 | $567,062.71 | 2,762,777 | |
| 1/4/2016 | Jonathan Sheena | CTO | Sell | 25,000 | $10.06 | $251,500.00 | 622,551 | |
| 12/31/2015 | Matthew Rabinowitz | CEO | Sell | 111,513 | $10.83 | $1,207,685.79 | 2,817,460 | |
| 12/29/2015 | Jonathan Sheena | CTO | Sell | 50,000 | $10.44 | $522,000.00 | 640,051 | |
| 12/29/2015 | Matthew Rabinowitz | CEO | Sell | 83,804 | $10.62 | $889,998.48 | 2,928,973 | |
| 7/8/2015 | James Healy | Director | Buy | 350,000 | $18.00 | $6,300,000.00 | | |
| 7/2/2015 | James Healy | Director | Buy | 400,000 | $22.81 | $9,124,000.00 | | |
(Data available from 1/1/2013 forward)
Natera (NASDAQ NTRA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Natera (NTRA) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 21 at 7:24 AM |
| ValuEngine Downgrades Natera (NTRA) to Strong Sell
www.americanbankingnews.com - April 16 at 7:35 PM |
| Natera (NTRA) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - April 16 at 8:18 AM |
| Natera Inc (NTRA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 11:29 AM |
| Natera (NTRA) & Its Peers Financial Review
www.americanbankingnews.com - April 15 at 7:21 AM |
| Natera (NTRA) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 5:18 PM |
| Natera (NTRA) vs. The Competition Head-To-Head Comparison
www.americanbankingnews.com - April 14 at 7:43 AM |
 | Natera to Present Successful Results at AACR from Bladder and Colon Cancer Studies
finance.yahoo.com - April 13 at 4:21 PM |
| Natera (NTRA) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 11 at 5:35 PM |
| Natera (NTRA) Lifted to Sell at ValuEngine
www.americanbankingnews.com - April 11 at 3:58 PM |
| Natera (NTRA) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 11 at 12:04 PM |
| Natera (NTRA) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM |
| Natera Inc (NTRA) Expected to Post Quarterly Sales of $55.51 Million
www.americanbankingnews.com - April 11 at 1:44 AM |
| Financial Analysis: Natera (NTRA) & Its Competitors
www.americanbankingnews.com - April 10 at 7:09 PM |
| Natera To Present New Data at ACMG Annual Meeting
finance.yahoo.com - April 10 at 10:01 AM |
| Natera Inc (NTRA) Expected to Announce Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 9 at 11:17 PM |
 | Benzinga's Top Upgrades, Downgrades For April 9, 2018
www.benzinga.com - April 9 at 9:51 AM |
 | Natera Appoints Paul R. Billings, MD, Ph.D., as Chief Medical Officer
www.prnewswire.com - April 9 at 9:51 AM |
| Natera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical Officer
finance.yahoo.com - April 9 at 9:51 AM |
| Natera (NTRA) Research Coverage Started at Craig Hallum
www.americanbankingnews.com - April 9 at 8:25 AM |
| Critical Survey: Natera (NTRA) & Its Rivals
www.americanbankingnews.com - April 8 at 3:08 AM |
| Natera (NTRA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 4 at 11:26 PM |
| Head-To-Head Review: Natera (NTRA) and The Competition
www.americanbankingnews.com - April 4 at 3:06 AM |
| Critical Review: Natera (NTRA) & Its Competitors
www.americanbankingnews.com - April 1 at 1:16 PM |
| Contrasting Natera (NTRA) and Its Competitors
www.americanbankingnews.com - March 31 at 11:16 PM |
 | Form 4 Natera, Inc. For: Mar 26 Filed by: Brophy Michael Burkes
www.streetinsider.com - March 29 at 10:03 AM |
 | Why Hemp Could Become the Next Biggest Cash Crop and How to Profit -- CFN Media
globenewswire.com - March 29 at 10:03 AM |
| Natera Inc (NTRA) CFO Michael Burkes Brophy Sells 1,449 Shares
www.americanbankingnews.com - March 28 at 11:10 PM |
| Insider Selling: Natera Inc (NTRA) COO Sells 1,997 Shares of Stock
www.americanbankingnews.com - March 28 at 11:10 PM |
| Natera (NTRA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 26 at 9:18 PM |
| Natera (NTRA) Lifted to Hold at BidaskClub
www.americanbankingnews.com - March 26 at 1:58 PM |
| Head to Head Comparison: BioM�rieux (BMXMF) and Natera (NTRA)
www.americanbankingnews.com - March 25 at 9:04 PM |
| $58.41 Million in Sales Expected for Natera Inc (NTRA) This Quarter
www.americanbankingnews.com - March 25 at 2:00 AM |
| BidaskClub Downgrades Natera (NTRA) to Strong Sell
www.americanbankingnews.com - March 24 at 8:23 PM |
| Contrasting Davita (DVA) and Natera (NTRA)
www.americanbankingnews.com - March 23 at 5:16 AM |
| Natera Inc (NTRA) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 21 at 11:27 AM |
| Natera (NTRA) and Its Competitors Financial Survey
www.americanbankingnews.com - March 18 at 1:20 PM |
| Edited Transcript of NTRA earnings conference call or presentation 13-Mar-18 9:00pm GMT
finance.yahoo.com - March 18 at 9:32 AM |
 | Natera's (NTRA) CEO Matthew Rabinowitz on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 14 at 10:41 AM |
| Natera Reports Fourth Quarter and Fiscal Year 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 14 at 10:41 AM |
 | 3 Stocks to Watch on Wednesday: Caleres Inc (CAL), Everi Holdings Inc (EVRI) and Natera Inc (NTRA) - Investorplace.com
investorplace.com - March 14 at 10:41 AM |
| 3 Stocks to Watch on Wednesday: Caleres Inc (CAL), Everi Holdings Inc (EVRI) and Natera Inc (NTRA)
investorplace.com - March 14 at 8:00 AM |
| Natera Reports Fourth Quarter and Fiscal Year 2017 Financial Results
finance.yahoo.com - March 13 at 6:12 PM |
 | Natera settles U.S. billing probe over prenatal gene tests for $11.4 mln
www.reuters.com - March 13 at 9:57 AM |
 | QIAGEN Ties Up With Natera, Boosts GeneReader NGS Platform
www.zacks.com - March 13 at 9:57 AM |
| QIAGEN and Natera Partner to Develop Cutting-Edge Genetic Testing Assays for Use on QIAGEN’s GeneReader NGS System
finance.yahoo.com - March 12 at 5:22 PM |
| Natera (NTRA) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 8 at 8:16 PM |
| Natera Inc. Announces Fourth Quarter and Fiscal 2017 Earnings Conference Call
www.prnewswire.com - March 7 at 8:19 PM |
| Natera Inc (NTRA) Expected to Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - March 6 at 5:08 PM |
| Natera's Genetic Tests Now Fully Integrated into Yale New Haven Health's Epic EMR System
finance.yahoo.com - March 5 at 4:53 PM |
Natera (NASDAQ:NTRA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Natera (NASDAQ:NTRA) Income Statement, Balance Sheet and Cash Flow Statement
Natera (NASDAQ NTRA) Stock Chart for Sunday, April, 22, 2018
Loading chart…
